ProQR Therapeutics
PRQR
35 hedge funds and large institutions have $173M invested in ProQR Therapeutics in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
33% more capital invested
Capital invested by funds: $130M → $173M (+$43M)
17% more funds holding
Funds holding: 30 → 35 (+5)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$13.3M |
| 2 |
PC
PointState Capital
New York
|
+$2.63M |
| 3 |
VAM
Visium Asset Management
New York
|
+$1.71M |
| 4 |
ClearBridge Investments
New York
|
+$1.54M |
| 5 |
AC
Ascend Capital
Orinda,
California
|
+$1.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$9.44M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.48M |
| 3 |
DM
Deerfield Management
New York
|
-$2.28M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.95M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.87M |
PRQR Hedge Fund Activity: Q4 2014 in Review
35 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2014, worth a combined $173M — up 33% from $130M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PRQR positions and 4 closed out — a net gain of 5 holders — while 11 added to existing stakes and 11 trimmed.
The largest buyer was OrbiMed, adding an estimated $13.3M. The largest seller was BVF Inc, exiting entirely with an estimated $9.44M sold.
- 35 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2014, up from 30 in Q3 2014.
- Funds reported $173M of ProQR Therapeutics stock for Q4 2014, up 33% quarter-over-quarter.
- 9 funds opened new ProQR Therapeutics positions in Q4 2014 and 4 closed out, a net change of +5 holders.
- The largest ProQR Therapeutics buyer in Q4 2014 was OrbiMed, an estimated $13.3M added.
- The largest ProQR Therapeutics seller in Q4 2014 was BVF Inc, an estimated $9.44M sold.
Based on aggregated 13F filings for Q4 2014.